161 related articles for article (PubMed ID: 25029560)
1. Cutaneous hemophagocytosis after alemtuzumab injection in a patient with Sézary syndrome.
Jawed SI; Busam K; Wang X; Horwitz S; Querfeld C
JAMA Dermatol; 2014 Sep; 150(9):1021-3. PubMed ID: 25029560
[No Abstract] [Full Text] [Related]
2. Plaques and tumors in a patient with refractory Sézary syndrome treated with mogamulizumab.
Ricci C; Pileri A; Agostinelli C; Ambrosi F; Zinzani PL; Sabattini E
J Dtsch Dermatol Ges; 2018 Oct; 16(10):1263-1265. PubMed ID: 30277017
[No Abstract] [Full Text] [Related]
3. Treatment of Sézary Syndrome With Alemtuzumab: A Series of 5 Cases and a Review of the Literature.
del Alcázar-Viladomiu E; Tuneu-Valls A; López-Pestaña A; Vidal-Manceñido MJ
Actas Dermosifiliogr; 2015 Sep; 106(7):e33-9. PubMed ID: 25960287
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary cryptococcoma in a patient with Sézary syndrome treated with alemtuzumab.
Hotz C; Ingen-Housz-Oro S; Tran Van Nhieu J; Charlier C; Foulet F; Rahmouni A; Zegai B; Duong TA; Wolkenstein P; Bagot M; Chosidow O
Eur J Dermatol; 2011; 21(6):1018-20. PubMed ID: 21926045
[No Abstract] [Full Text] [Related]
5. Can the level of CD52 expression on Sézary cells be used to predict the response of Sézary syndrome to alemtuzumab?
Fernandes IC; Gonçalves M; dos Anjos Teixeira M; Gonçalves C; Coutinho J; Selores M; Alves R; Lima M
J Am Acad Dermatol; 2012 Nov; 67(5):1083-5. PubMed ID: 23062898
[No Abstract] [Full Text] [Related]
6. Alemtuzumab in refractory Sézary syndrome.
Reifs CM; Salido-Vallejo R; Garnacho-Saucedo GM; Corte-Sánchez S; González-Menchen A; García-Nieto AV
An Bras Dermatol; 2016; 91(5):642-644. PubMed ID: 27828640
[TBL] [Abstract][Full Text] [Related]
7. Hemophagocytic syndrome induced by diaminodiphenylsulfone.
Hiura Y; Kawabata H; Kanekura T; Terasaki K; Kanzaki T
J Dermatol; 2007 Oct; 34(10):730-1. PubMed ID: 17908150
[No Abstract] [Full Text] [Related]
8. Alemtuzumab-resistant Sézary syndrome responding to zanolimumab.
Alexandroff AB; Shpadaruk V; Bamford WM; Kennedy DB; Burd R; Dyer MJ
Br J Haematol; 2011 Aug; 154(3):419-21. PubMed ID: 21480857
[No Abstract] [Full Text] [Related]
9. Scarring alopecia developing after mogamulizumab-associated rash.
Raval NS; Snowden CK; De Monnin KS; Yokoyama CC; Choi J; Mehta-Shah N; Rosman IS; Pavlisin J; Musiek AC
Eur J Dermatol; 2021 Dec; 31(6):841-843. PubMed ID: 35107074
[No Abstract] [Full Text] [Related]
10. Alemtuzumab treatment for Sézary syndrome: A single-center experience.
Novelli S; García-Muret P; Sierra J; Briones J
J Dermatolog Treat; 2016; 27(2):179-81. PubMed ID: 26329989
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab in Sézary syndrome: efficient but not innocent.
Ure UB; Ar MC; Salihoglu A; Guner SI; Baran A; Oguz O; Ferhanoglu B
Eur J Dermatol; 2007; 17(6):525-9. PubMed ID: 17951134
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H).
Gautschi O; Blumenthal N; Streit M; Solenthaler M; Hunziker T; Zenhäusern R
Eur J Haematol; 2004 Jan; 72(1):61-3. PubMed ID: 14962265
[TBL] [Abstract][Full Text] [Related]
13. Transformation of Sézary syndrome into CD30+ anaplastic large T-cell lymphoma after alemtuzumab therapy with evidence of clonal unity.
Nevet MJ; Zuckerman T; Sahar D; Bergman R
Am J Dermatopathol; 2015 Jan; 37(1):73-7. PubMed ID: 25548993
[TBL] [Abstract][Full Text] [Related]
14. Sézary syndrome associated with granulomatous lesions during treatment with bexarotene.
Ruiz-de-Casas A; Carrizosa-Esquivel A; Herrera-Saval A; Rios-Martín JJ; Camacho F
Br J Dermatol; 2006 Feb; 154(2):372-4. PubMed ID: 16433814
[TBL] [Abstract][Full Text] [Related]
15. Mogamulizumab-induced vitiligo in patients with Sézary syndrome: three cases.
Algarni AS; Ram-Wolff C; Bagot M; De Masson A
Eur J Dermatol; 2021 Apr; 31(2):213-216. PubMed ID: 33814357
[TBL] [Abstract][Full Text] [Related]
16. Sezary syndrome presenting with leonine facies and treated with low-dose subcutaneous alemtuzumab.
Oliveira A; Lobo I; Alves R; Lima M; Selores M
Dermatol Online J; 2011 Nov; 17(11):6. PubMed ID: 22136862
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab treatment for hemophagocytic lymphohistiocytosis.
Machaczka M; Vaktnäs J; Chiang SC; Bryceson YT
Nat Rev Clin Oncol; 2010 Oct; 7(10):. PubMed ID: 21080519
[No Abstract] [Full Text] [Related]
18. Mogamulizumab-induced toxicoderma-like eruptions and autoimmune hepatitis successfully treated with azathioprine in adult T-cell leukaemia/lymphoma.
Nishizawa A; Ishikawa T; Hirose M; Satoh H; Nishii S; Tomita K; Hokari R; Satoh T
Eur J Dermatol; 2017 Dec; 27(6):651-652. PubMed ID: 28739547
[No Abstract] [Full Text] [Related]
19. Multiple abscesses in a patient treated with cetuximab.
Ricci F; Guerriero C; Paradisi A; Fossati B; Miccichè F; Valentini V; Capizzi R
Eur J Dermatol; 2013; 23(1):103-4. PubMed ID: 23238287
[No Abstract] [Full Text] [Related]
20. Association of autoimmunity and long-term complete remission in patients with Sézary syndrome treated with mogamulizumab.
Bonnet P; Battistella M; Roelens M; Ram-Wolff C; Herms F; Frumholtz L; Bouaziz JD; Brice P; Moins-Teisserenc H; Bagot M; de Masson A
Br J Dermatol; 2019 Feb; 180(2):419-420. PubMed ID: 30328116
[No Abstract] [Full Text] [Related]
[Next] [New Search]
